Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METRA vs METRO I.V. IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metformin primarily decreases hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK), leading to reduced gluconeogenesis and increased peripheral glucose uptake.
Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.
Type 2 diabetes mellitus,Polycystic ovary syndrome (off-label)
Treatment of intra-abdominal infections (peritonitis, intra-abdominal abscess),Treatment of bacterial vaginosis,Treatment of trichomoniasis,Treatment of amebiasis (amebic dysentery and amebic liver abscess),Treatment of skin and skin structure infections (decubitus ulcers, infected wounds),Treatment of gynecologic infections (endometritis, tubo-ovarian abscess),Treatment of central nervous system infections (meningitis, brain abscess),Treatment of septicemia and endocarditis,Off-label: Perioperative prophylaxis for colorectal surgery,Off-label: Treatment of Helicobacter pylori infection (combined with other agents),Off-label: Crohn's disease (perianal fistulas)
Adults: 20 mg orally once daily.
IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.
Terminal elimination half-life: 3-7 hours (mean 4.5 hours). Increased to 8-15 hours in moderate-to-severe renal impairment (Cr Cl <30 m L/min).
8 hours (6-12 hours) in adults; prolonged in hepatic impairment
Metformin is excreted unchanged in urine; does not undergo hepatic metabolism or cytochrome P450 metabolism.
Hepatic metabolism via oxidation and glucuronidation, primarily by CYP450 enzymes (CYP2A6, CYP3A4). The major metabolites are hydroxymetronidazole and metronidazole glucuronide.
Primarily renal: 70-80% unchanged drug via glomerular filtration and active tubular secretion; 15-20% biliary/fecal as metabolites.
Renal (60-80% as unchanged drug), fecal (6-15%), biliary (small amount)
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein.
<20% bound to plasma proteins
Vd: 1.5-2.5 L/kg (mean 2.0 L/kg). Extensive tissue distribution; crosses blood-brain barrier and placenta.
0.25-0.85 L/kg; indicates wide distribution into tissues including CSF
Oral: 60-75% (due to first-pass metabolism); intramuscular: 90-100%; topical: 10-20% (formulation-dependent).
100% intravenous
e GFR ≥30 m L/min: no adjustment; e GFR <30 m L/min: 10 mg once daily.
Cr Cl 10-50 m L/min: 500 mg every 12 h. Cr Cl <10 m L/min: 500 mg every 24 h. Hemodialysis: dose after dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: 10 mg once daily; Child-Pugh C: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B or C: reduce dose by 50% (e.g., 500 mg every 12 h).
Weight ≥30 kg: 20 mg once daily; weight <30 kg: 10 mg once daily.
Neonates (GA <34 wk): 7.5 mg/kg every 12 h; (GA ≥34 wk): 7.5 mg/kg every 8 h. Infants/children: 10 mg/kg every 6-8 h. Max 4 g/day.
≥65 years: initial dose 10 mg once daily, titrate as tolerated.
Cr Cl 10-50 m L/min: 500 mg every 12 h. Cr Cl <10 m L/min: 500 mg every 24 h. Monitor for neurotoxicity.
Lactic acidosis: Metformin use has been associated with lactic acidosis, a rare but serious metabolic complication. Risk factors include renal impairment, concomitant use of certain drugs, age ≥65 years, and hepatic disease.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Unnecessary use should be avoided.
Lactic acidosis risk, impaired renal function (monitor e GFR), vitamin B12 deficiency, acute metabolic acidosis, perioperative use, and concurrent iodinated contrast agents.
May cause seizures and peripheral neuropathy; discontinue if neurologic symptoms occur.,Use caution in patients with central nervous system disorders.,Blood dyscrasias: Use with caution in patients with history of or current blood dyscrasias.,Hepatic impairment: Dose adjustment may be required.,Carcinogenicity: Avoid prolonged or unnecessary use.,Drug interactions: Potentiation of anticoagulant effect of warfarin; disulfiram-like reaction with alcohol.,Prolonged QT interval: Use with caution with QT-prolonging agents.,Superinfection: May cause overgrowth of Clostridioides difficile.
Severe renal impairment (e GFR <30 m L/min/1.73 m²), acute metabolic acidosis, severe hepatic disease, and hypersensitivity to metformin.
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (relative contraindication; use only if clearly needed),Breastfeeding (manufacturer recommends discontinuation of nursing or drug, but AAP considers compatible),Use with disulfiram (within 2 weeks of disulfiram administration),Use with alcohol or propylene glycol-containing products (due to disulfiram-like reaction)
Avoid high-sodium foods as they may counteract the antihypertensive effect. Consumption of potassium-rich foods (e.g., bananas, oranges) is not restricted unless hypokalemia develops, but monitor potassium levels. Grapefruit juice may increase metolazone absorption; avoid concurrent use. Limit alcohol intake as it may enhance hypotensive effects.
Avoid alcohol and any foods or beverages containing alcohol (e.g., beer, wine, liquor, some vinegars, certain desserts) for 48 hours after last dose. No other significant food interactions.
METRA is contraindicated in pregnancy due to documented teratogenicity, including neural tube defects, cardiovascular malformations, and craniofacial abnormalities in first trimester. Second and third trimester exposure may cause low birth weight and transient neonatal metabolic disturbances. Use effective contraception during treatment.
Metronidazole crosses the placenta. In the first trimester, data are conflicting but meta-analyses show no significant increase in major malformations; however, some studies suggest a possible small risk of cleft palate. The CDC and FDA consider it contraindicated in the first trimester unless clearly needed. In the second and third trimesters, it is generally considered safe, but caution is advised near term due to potential neonatal accumulation.
METRA is excreted into human breast milk with an M/P ratio of approximately 0.8 to 1.2. Due to potential adverse effects in nursing infants, such as immunosuppression and growth delay, breastfeeding is not recommended during therapy and for 12 months after last dose.
Metronidazole is excreted into breast milk with milk-to-plasma ratio of approximately 0.6-1.0. Peak milk concentrations occur 2-4 hours after dose. The American Academy of Pediatrics considers it compatible with breastfeeding, but some sources advise discarding milk for 12-24 hours after a single high dose (2 g) to reduce infant exposure. For standard dosing, benefits likely outweigh risks.
No dosing adjustments are recommended because METRA is contraindicated in pregnancy. In the rare event of inadvertent use during pregnancy, immediate discontinuation is required. Pharmacokinetic changes in pregnancy (increased clearance, reduced protein binding) do not apply as therapy must be ceased.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic clearance) may reduce serum concentrations of metronidazole, but the clinical significance is unclear. No dose adjustment is routinely recommended; however, for serious infections, therapeutic drug monitoring may be considered. Standard dosing (e.g., 500 mg IV every 8 hours) is typically used.
METRA is a brand name for metolazone, a thiazide-like diuretic. Use with caution in severe renal impairment (e GFR <20 m L/min) as effectiveness diminishes. Monitor for hypokalemia, especially when used with loop diuretics. Do not use in hepatic coma or pre-coma.
Metronidazole IV exhibits excellent bioavailability; oral and IV dosing are equivalent. Avoid ethanol-containing medications or diet due to disulfiram-like reaction. Monitor for peripheral neuropathy with prolonged use. Adjust dose in severe hepatic impairment (Child-Pugh C).
Take exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,May cause dizziness or lightheadedness due to blood pressure changes; rise slowly from sitting or lying positions.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or extreme thirst.,Do not consume alcohol or take other blood pressure medications without consulting your doctor.
Do not consume alcohol or products containing propylene glycol during treatment and for at least 48 hours after completion.,Report any numbness, tingling, or burning in hands or feet immediately.,Complete the full course as prescribed even if symptoms improve.,May cause metallic or bitter taste; this is temporary and harmless.
"Concurrent use of Phenmetrazine, a sympathomimetic amine with central nervous system stimulant activity, and Isoxsuprine, a beta-adrenergic receptor agonist with peripheral vasodilatory effects, may result in additive stimulation of the cardiovascular system. This can lead to synergistic increases in heart rate, myocardial contractility, and blood pressure, potentially precipitating hypertensive crisis, tachycardia, arrhythmias, or myocardial ischemia. Clinically, this interaction poses significant risks for patients with underlying cardiovascular disease, and careful monitoring is essential if concomitant use is unavoidable."
"The combination of Phenmetrazine, a sympathomimetic appetite suppressant, with Oxymetazoline, a direct-acting alpha-adrenergic agonist, can lead to additive vasoconstriction and hypertensive effects. This interaction may precipitate a hypertensive crisis, especially in patients with underlying cardiovascular disease, and can result in adverse outcomes such as myocardial ischemia, stroke, or arrhythmias. Concurrent use should be avoided due to the potential for severe cardiovascular adverse events."
"Amphetamine and phenmetrazine are both central nervous system (CNS) stimulants that increase synaptic norepinephrine and dopamine by promoting release and blocking reuptake. Concurrent use synergistically amplifies adrenergic and dopaminergic signaling, leading to excessive CNS stimulation and cardiovascular strain. This can manifest as severe hypertension, tachyarrhythmia, hyperthermia, agitation, serotonin syndrome-like symptoms, and potentially life-threatening events such as stroke or myocardial infarction."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METRA vs METRO I.V. IN PLASTIC CONTAINER, answered by our medical review team.
METRA is a Antibiotic (Nitroimidazole) that works by Metformin primarily decreases hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK), leading to reduced gluconeogenesis and increased peripheral glucose uptake.. METRO I.V. IN PLASTIC CONTAINER is a Antibiotic (Nitroimidazole) that works by Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METRA and METRO I.V. IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METRA is: Adults: 20 mg orally once daily.. The standard adult dose of METRO I.V. IN PLASTIC CONTAINER is: IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METRA and METRO I.V. IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METRA is classified as Category C. METRA is contraindicated in pregnancy due to documented teratogenicity, including neural tube defects, cardiovascular malformations, and craniofacial abnormalities in first trimest. METRO I.V. IN PLASTIC CONTAINER is classified as Category C. Metronidazole crosses the placenta. In the first trimester, data are conflicting but meta-analyses show no significant increase in major malformations; however, some studies sugges. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.